
|Articles|April 1, 2003
Price Tag Holds Back Biologics for Psoriasis
The use of biologics to treat psoriasis is on the move. A couple of systemic medications have received FDA approval for psoriasis and related conditions, and several more are in the pipeline. Although the drugs are reputed to cause fewer and less serious side effects than traditional psoriasis treatments, that doesn't mean side effects don't exist, and that makes them an issue for some doctors and patients alike.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
4
Introducing Dermatology Times NP/PA Connect
5











